Tech Company Financing Transactions
LeukoSight Funding Round
On 3/31/2009, LeukoSight received $150 thousand in funding from TEDCO.
Transaction Overview
Company Name
Announced On
3/31/2009
Transaction Type
Venture Equity
Amount
$150,000
Round
Undisclosed
Investors
TEDCO (Mark Grovi)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1107 Microbiology Building
College Park, MD 20742
USA
College Park, MD 20742
USA
Phone
Website
Email Address
Overview
LeukoSight Inc. is an early stage biotechnology company developing a line of novel therapeutics that can be used to treat autoimmune and inflammatory diseases. LeukoSight's technology promises to offer a convenient, safe and more effective treatment option for these diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Mosser
Browse more venture capital transactions:
Prev: 3/31/2009: Inogen venture capital transaction
Next: 3/31/2009: Network Vision venture capital transaction
Share this article
Where The Data Comes From
We record funding rounds that are announced publicly. VC investment data records reported here are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs